Degarelix
- Generic Name
- Degarelix
- Brand Names
- Firmagon, Degarelix Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C82H103ClN18O16
- CAS Number
- 214766-78-6
- Unique Ingredient Identifier
- SX0XJI3A11
- Background
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone s...
- Indication
Degaralix is used for the management of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- -
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 182
- Registration Number
- NCT00884273
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Ospedali riuniti, Ancona, Italy
🇧🇪Institut Jules Bordet, Bruxelles, Belgium
🇫🇮KYS/kirurgian klin (Kuopio), Kuopio, Finland
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 246
- Registration Number
- NCT00833248
- Locations
- 🇬🇧
Kent Oncology Centre Maidstone Hospital, Maidstone, Kent, United Kingdom
🇫🇷Clinique du Parc, Toulouse, France
🇫🇷Centre de Lutte Contre le Cancer Nantes-Atlantique Centre René Gauducheau, Saint Herblain Cedex, France
Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT00831233
- Locations
- 🇪🇸
Fundación Puigvert, Barcelona, Spain
🇪🇸Fundacion Hospital Alcorcón, Alcorcon, Spain
🇪🇸Hospital de Basurto, Bilbao (Bizkaia), Spain
Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 189
- Registration Number
- NCT00819156
- Locations
- 🇧🇪
UZ Gasthuisberg, Leuven, Belgium
🇩🇪Urologische Universitätsklinikum, Mannheim, Germany
🇭🇺Pez Aladar County Hospital, Györ, Hungary
Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 172
- Registration Number
- NCT00818623
- Locations
- 🇩🇰
KAS Herlev, Herlev, Denmark
🇸🇪Sahlgrenska Universitetssjukehuset, Göteborg, Sweden
🇫🇮TAYS, Tampere, Finland
The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 129
- Registration Number
- NCT00819247
- Locations
- 🇬🇧
Kings College Hospital, London, United Kingdom
🇬🇧Stirling Royal Infirmary, Stirling, United Kingdom
🇬🇧Bristol Royal Infirmary, Bristol, United Kingdom
Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT00738673
- Locations
- 🇩🇪
Wissenschaftskontor Nord, Rostock, Germany
🇩🇪Martini Klinik, Hamburg, Germany
🇩🇪Urologische Klinik, Planegg, Germany
Open-Label, Randomised Parallel-Group Study
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2011-03-18
- Lead Sponsor
- Ferring Pharmaceuticals
- Registration Number
- NCT00728533
Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT00527488
- Locations
- 🇩🇪
CRS Clinical Research Services Monchengladback GmbH, Monchengladbach, Germany
Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy
- First Posted Date
- 2007-05-02
- Last Posted Date
- 2011-03-23
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 133
- Registration Number
- NCT00468286
- Locations
- 🇺🇸
Regional Urology, Shreveport, Louisiana, United States
🇺🇸The Urology Center, Greensboro, North Carolina, United States
🇺🇸State College Urologic Association, State College, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.